The most frequently reported adverse reactions were rash, pain in extremity, pruritus, and somnolence.
Raxibacumab is a human IgG1? monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Raxibacumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Raxibacumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Raxibacumab. |
| Estrone | Estrone may increase the thrombogenic activities of Raxibacumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Raxibacumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Raxibacumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Raxibacumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Raxibacumab. |
| Estriol | Estriol may increase the thrombogenic activities of Raxibacumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Raxibacumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Raxibacumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Raxibacumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Raxibacumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Raxibacumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Raxibacumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Raxibacumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Raxibacumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Raxibacumab. |
| Equol | Equol may increase the thrombogenic activities of Raxibacumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Raxibacumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Raxibacumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Raxibacumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Raxibacumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Raxibacumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Raxibacumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Raxibacumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Raxibacumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Raxibacumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Raxibacumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Raxibacumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Raxibacumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Raxibacumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Raxibacumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Raxibacumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Raxibacumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Raxibacumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Raxibacumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Raxibacumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Raxibacumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Raxibacumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Raxibacumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Raxibacumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Raxibacumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raxibacumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Raxibacumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Raxibacumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raxibacumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Raxibacumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Raxibacumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Raxibacumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Raxibacumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Raxibacumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Raxibacumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Raxibacumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Raxibacumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Raxibacumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Raxibacumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Raxibacumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Raxibacumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Raxibacumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Raxibacumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Raxibacumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Raxibacumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Raxibacumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Raxibacumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Raxibacumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Raxibacumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Raxibacumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Raxibacumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Raxibacumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Raxibacumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Raxibacumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Raxibacumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Raxibacumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Raxibacumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Raxibacumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Raxibacumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Raxibacumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Raxibacumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Raxibacumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Raxibacumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Raxibacumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Raxibacumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Raxibacumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Raxibacumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Raxibacumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Raxibacumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Raxibacumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Raxibacumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Raxibacumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Raxibacumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Raxibacumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Raxibacumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Raxibacumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Raxibacumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Raxibacumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Raxibacumab. |